Keros Therapeutics

Jasbir Seehra

Keros Therapeutics, CEO

Dr. Jasbir Seehra is the Founder and serves as Chief Executive Officer, President & Board Member at Keros Therapeutics. He also served as the Chief Scientific Officer at Ember Therapeutics. He joined Ember as chief scientific officer in 2012; and served on the scientific advisory board since the company was founded. Dr. Seehra is formerly the chief scientific officer of Acceleron Pharma, Inc., which he co-founded in 2003. Dr. Seehra has more than 25 years of experience in drug discovery, including having served as vice president of biological chemistry at Wyeth and a drug discovery consultant to AVEO Pharmaceuticals, Inc. Prior to that, he led the small molecule lead discovery effort at Genetics Institute, Inc. where he started as a bench scientist and held numerous positions with increasing responsibility. At Genetics Institute, Dr. Seehra successfully built the institute's small molecule drug discovery capabilities, including medicinal chemistry, high throughput screening and structural biology. Dr. Seehra has authored numerous publications and is an inventor on 33 patents. Dr. Seehra received his B.S. and Ph.D. in biochemistry from the University of Southampton in England. He completed his postdoctoral work at the Massachusetts Institute of Technology.

Keith Regnante

Keros Therapeutics, CFO

Keith Regnante has served as our Chief Financial Officer since February 2020. Prior to joining us, from August 2016 to January 2020, Mr. Regnante served as Chief Financial Officer at Wave Life Sciences Ltd. From February 2014 to August 2016, Mr. Regnante served as Vice President of Finance at Shire Pharmaceuticals, or Shire, a global biopharmaceutical company. Mr. Regnante also served on the Financial Leadership Team and the R&D Leadership Team while he was at Shire. From September 2013 to February 2014, he served as Head of R&D Finance for ARIAD Pharmaceuticals, Inc. From January 1999 to August 2013, Mr. Regnante held multiple finance positions at Biogen Inc., including Senior Director of Corporate Finance from 2011 to 2013, Senior Director of Worldwide R&D Finance from 2008 to 2011 and several other positions dating back to 1999. Prior to joining finance organizations for biotechnology companies, Mr. Regnante worked as a consultant at The Boston Consulting Group. He holds a B.A. in Economics from Tufts University and an M.B.A. from the MIT Sloan School of Management.